← Back to Analyst Consensus 
TYRA Buy
Tyra Biosciences, Inc.
Current Price —
Implied Upside —
Analysts 21
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 0 reiterations from 0 firms
Next Earnings
Nov 3, 2026 (8 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Sep 22, 2026 | Oppenheimer | reiterate | Outperform → Outperform | — | 52% |
| Sep 22, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | — | 44% |
| Sep 10, 2026 | Wedbush | reiterate | Outperform → Outperform | — | 58% |
| Sep 10, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | — | 44% |
| Sep 4, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Jun 17, 2026 | Jones Trading | initiate | — → Buy | — | 50% |
| Jun 10, 2026 | B of A Securities | maintain | Buy → Buy | — | 53% |
| May 19, 2026 | Wolfe Research | initiate | — → Peer Perform | — | 53% |
| May 14, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Apr 15, 2026 | Guggenheim | initiate | — → Buy | — | 52% |
| Apr 6, 2026 | Canaccord Genuity | initiate | — → Buy | — | 48% |
| Mar 20, 2026 | Piper Sandler | maintain | Overweight → Overweight | — | 54% |
| Feb 24, 2026 | Cantor Fitzgerald | initiate | — → Overweight | $0 | 50% |
| Feb 17, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | $45 | 44% |
| Feb 13, 2026 | Wedbush | maintain | Outperform → Outperform | $53 | 58% |
| Feb 3, 2026 | Oppenheimer | maintain | Outperform → Outperform | $50 | 52% |
| Feb 3, 2026 | Jefferies | maintain | Buy → Buy | $43 | 52% |
| Jan 28, 2026 | Barclays | initiate | — → Overweight | $59 | 53% |
| Jan 23, 2026 | Piper Sandler | maintain | Overweight → Overweight | $42 | 54% |
| Dec 16, 2025 | Wedbush | maintain | Outperform → Outperform | $37 | 58% |
| Sep 3, 2025 | Raymond James | initiate | — → Strong Buy | $35 | 54% |
| Aug 22, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $30 | 44% |
| Jul 1, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $30 | 44% |
| Mar 31, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $30 | 44% |
| Feb 18, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $30 | 44% |
| Jan 13, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $30 | 44% |
| Jan 7, 2025 | UBS | initiate | — → Buy | $28 | 54% |
| Nov 11, 2024 | HC Wainwright & Co. | maintain | Buy → Buy | $30 | 44% |
| Oct 29, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $32 | 44% |
| Oct 28, 2024 | HC Wainwright & Co. | maintain | Buy → Buy | $32 | 44% |
| Oct 25, 2024 | Wedbush | reiterate | Outperform → Outperform | $28 | 58% |
| Oct 18, 2024 | B of A Securities | upgrade | Neutral → Buy | $31 | 53% |
| Oct 7, 2024 | HC Wainwright & Co. | maintain | Buy → Buy | $30 | 44% |
| Sep 19, 2024 | Oppenheimer | maintain | Outperform → Outperform | $33 | 52% |
| Aug 15, 2024 | Piper Sandler | initiate | — → Overweight | $33 | 54% |
| Aug 8, 2024 | Wedbush | reiterate | Outperform → Outperform | $28 | 58% |
| Aug 8, 2024 | Oppenheimer | maintain | Outperform → Outperform | $25 | 52% |
| Jul 3, 2024 | Oppenheimer | reiterate | Outperform → Outperform | $28 | 52% |
| Jul 3, 2024 | Wedbush | reiterate | Outperform → Outperform | $28 | 58% |
| Jul 3, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $23 | 44% |
| Jun 5, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $23 | 44% |
| May 13, 2024 | Oppenheimer | reiterate | Outperform → Outperform | $28 | 52% |
| May 10, 2024 | Wedbush | reiterate | Outperform → Outperform | $28 | 58% |
| May 10, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $23 | 44% |
| Mar 21, 2024 | Wedbush | reiterate | Outperform → Outperform | $28 | 58% |
| Mar 20, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $23 | 44% |
| Dec 29, 2023 | Wedbush | reiterate | Outperform → Outperform | $27 | 58% |
| Dec 26, 2023 | HC Wainwright & Co. | reiterate | Buy → Buy | $19 | 44% |
| Nov 8, 2023 | HC Wainwright & Co. | maintain | Buy → Buy | $19 | 44% |
| Aug 11, 2023 | Wedbush | reiterate | Outperform → Outperform | $27 | 58% |
Price Target Trend
Jul 8, 2026 Oct 26, 2026
EPS Estimates
0y —
0q —
+1q —
+1y —
Cross-Platform Signals
No cross-platform signals in the last 90 days